Ray Barlow, SynOx Therapeutics CEO
April 22, 2024 03:30 AM EDT
Financing

Irish biotech col­lects $75M in Se­ries B to start Phase 3 rare joint tu­mor tri­al

Ayisha Sharma

News Reporter

Syn­Ox Ther­a­peu­tics has com­plet­ed a $75 mil­lion Se­ries B raise to ad­vance its mon­o­clon­al an­ti­body drug through a reg­is­tra­tional tri­al for a type of non …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

A service from the Financial Times